2007
DOI: 10.1186/ar2315
|View full text |Cite
|
Sign up to set email alerts
|

Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study

Abstract: We performed a randomized, double-blind, placebo-controlled, multicenter, parallel-group, dose-response study of the efficacy and safety of the oral administration of PG-116800, a matrix metalloproteinase (MMP) inhibitor, in patients with mild to moderate knee osteoarthritis. The primary efficacy endpoints included the progression of joint space narrowing in the osteoarthritic knee, as measured by microfocal radiography with fluoroscopic positioning, and the reduction of symptoms (pain and stiffness) and/or th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
114
1
1

Year Published

2008
2008
2024
2024

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 168 publications
(118 citation statements)
references
References 34 publications
2
114
1
1
Order By: Relevance
“…It is possible that inhibition of multiple MMPs may lead to relatively higher efficacy. However, utility of broadspectrum MMP inhibitors for treatment of OA is limited by MSS liability (37). Therefore, we included assessment of MSS liability as a critical component of our effort to develop MMP-13 inhibitors for OA.…”
Section: Discussionmentioning
confidence: 99%
“…It is possible that inhibition of multiple MMPs may lead to relatively higher efficacy. However, utility of broadspectrum MMP inhibitors for treatment of OA is limited by MSS liability (37). Therefore, we included assessment of MSS liability as a critical component of our effort to develop MMP-13 inhibitors for OA.…”
Section: Discussionmentioning
confidence: 99%
“…In animal models of OA, MMP inhibitors can prevent cartilage degradation and joint damage [31]. However, in clinical trials, oral administration of PG-116800 (a broadspectrum MMP inhibitor with high affinity for MMP-2, MMP-3, MMP-8, MMP-9, MMP-13, and MMP-14) showed adverse musculoskeletal effects, such as arthralgia, fibrosis, or contracture [36]. However, local administration of MMP inhibitors for meniscal repair procedures should minimize any toxicities.…”
Section: Resultsmentioning
confidence: 99%
“…Clinical adverse events were reviewed as an additional supporting approach to evaluate crossreactivity, by comparison of the adverse events noted in seropositive subjects with those described in the published literature following the use of broad-spectrum MMP inhibitors in clinical trials (1,14). These products have been studied in clinical trial settings for potential therapeutic indications, including oncology uses and osteoarthritis.…”
Section: Discussionmentioning
confidence: 99%